Imbruvica (ibrutinib) - AbbVie, J&J
bosutinib - Generic mfg.
Alecensa (alectinib) - Roche
pazopanib - Generic mfg.
imatinib - Generic mfg.
Iclusig (ponatinib) - Takeda
Lenvima (lenvatinib) - Eisai, Merck (MSD)
Stivarga (regorafenib) - Bayer
dasatinib - Generic mfg.
nilotinib - Generic mfg.
sunitinib - Generic mfg.
Mekinist (trametinib) - Novartis, BeOne Medicines
Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. (PubMed, Clin Pharmacokinet) - Sep 5, 2026 - "Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies." 
Journal • PK/PD data • Hematological Disorders • Oncology
http://www.ncbi.nlm.nih.gov/pubmed/42696096
 
Anouk Dontje; Anthonie J van der Wekken; Bahez Gareb; Daan J Touw; Esther Broekman; Marjolijn N Lub-de Hooge; Paola Mian; Saskia K Klein; Thijs H Oude Munnink; Zaid N Al Shirity
 
Sep 5, 2026
 
Prev Next